Japanese manufacturers on issues related to product inspection data and quality management before the U.S. Department of Justice and other government authorities. 

A Japanese medical equipment manufacturer on quality management issues before the U.S. Food and Drug Administration and the U.S. Department of Justice.

Japan-based manufacturers and financial institutions in various cartel investigations and the follow-on federal class action lawsuits.

Major Japanese companies and their subsidiaries in potential FCPA violation matters and internal investigations.

Numerous Japan-based manufacturers and financial institutions on compliance issues, including antitrust, anti-corruption, litigation and product quality management.

One of the major Japanese companies and its affiliates in a potential FCPA violation matter and internal investigation.

One of the major Japanese companies and its Japanese subsidiary in an employment litigation matter in the U.S.

A Japanese medical equipment manufacturer on quality management issues before the U.S. Food and Drug Administration and the U.S. Department of Justice.

Japanese manufacturers in their internal investigations and potential government proceedings and litigation in connection with issues related to product inspection data.

Numerous Japan-based manufacturers and financial institutions on compliance issues, including antitrust, anti-corruption, litigation and product quality management.

Numerous Japan-based manufacturers in antitrust-related putative class actions and other civil disputes.

Numerous Japan-based manufacturers on merger clearance issues.

Japan-based manufacturers and financial institutions in various non-public cartel investigations and the follow-on federal class action lawsuits.

Executives of Japan-based corporations in non-public cartel investigations.

Japan Bank for International Cooperation in connection with various compliance-related matters.

Japan-based manufacturers and financial institutions on compliance issues, including antitrust and disclosure matters.

Establishment of ADR programs for Japanese corporations.

Maeda Corporation involving the filing of a Form CB in connection with its $3.3 billion joint share transfer with Maeda Road Construction and Maeda Seisakusho to establish a joint holding company.
Sawai Pharmaceutical Co., Ltd. regarding a registration with the U.S. Securities and Exchange Commission on Form F-4 in connection with the sole share transfer to establish Sawai Group Holdings Co., Ltd. as a holding company.

Japan Exchange Group, Inc. in a $48.4 million tender offer for shares of common stock and non-voting stock of Tokyo Commodity Exchange, Inc.

Sompo Holdings, Inc. in its $6.3 billion acquisition of Endurance Specialty Holdings Ltd.

Idemitsu Kosan Co., Ltd. and Showa Shell Sekiyu K.K., both Japanese petroleum companies, in connection with their $5.8 billion merger involving filings with the SEC.

The Joyo Bank, Ltd. and Ashikaga Holdings Co., Ltd., both Japanese regional banks, in connection with a $5.3 billion business integration involving filings with the SEC.

Yamaha Corporation in its acquisition of Line 6, Inc.

Japanese corporations in antitrust analysis in connection with their potential merger deals.